52U.F HYLORIS PHARMA. S.A.
- Market cap
- EUR 115M
- P/E
- -
- P/B
- 4.67x
- ROE
- -23.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 52U.F undervalued?
Graham numberThe Graham number of HYLORIS PHARMA. S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
HYLORIS PHARMA. S.A. fundamental analysis
No fundamental analysis for HYLORIS PHARMA. S.A. yet.
HYLORIS PHARMA. S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About HYLORIS PHARMA. S.A.
Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain; Podofilox gel, a topical antimycotic drug for external genital and perianal warts; Sotalol IV, an intravenous formulation of sotalol for the treatment of atrial fibrillation, and life-threatening ventricular arrhythmias; and Valacyclovir oral suspen…
Full company profileHYLORIS PHARMA. S.A. financial statements
HYLORIS PHARMA. S.A. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 3.10M | 900K | 2.09M | 8.46M | 7.21M |
| Gross Profit | 2.99M | 806K | 1.99M | 8.23M | 6.83M |
| Operating Income | -10.3M | -11.5M | -15.8M | -6.37M | -7.71M |
| EBITDA | - | -11.5M | -15.0M | -5.62M | -5.92M |
| Net Income | -11.6M | -11.9M | -15.4M | -6.34M | -6.33M |
| EPS | -0.45 | -0.43 | -0.55 | -0.23 | -0.23 |
| Balance Sheet | |||||
| Total Assets | 63.4M | 60.7M | 47.7M | 41.3M | 33.4M |
| Total Liabilities | 15.4M | 6.82M | 8.61M | 9.19M | 6.88M |
| Shareholders' Equity | 48.1M | 53.9M | 39.1M | 32.1M | 26.5M |
| Cash & Short-term Investments | 50.0M | 33.5M | 30.4M | 23.6M | 13.8M |
| Cash Flow | |||||
| Operating Cash Flow | -11.3M | -13.0M | -12.8M | -7.19M | -6.99M |
| Capital Expenditure | 1.06M | 739K | 750K | 298K | 629K |
| Free Cash Flow | -12.3M | -13.8M | -13.6M | -7.49M | -7.62M |
| Ratios | |||||
| ROE | -24.1% | -22.1% | -39.4% | -19.7% | -23.9% |
| ROA | -18.3% | -19.6% | -32.3% | -15.3% | -19.0% |
| Net Profit Margin | -374.0% | -1,322.9% | -736.9% | -75.0% | -87.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
HYLORIS PHARMA. S.A. dividends
HYLORIS PHARMA. S.A. has not paid dividends in the last 5 fiscal years.
Who owns HYLORIS PHARMA. S.A.
- Insiders 55.76%
- Institutions 0.00%
- Public & others 44.24%
- Shares outstanding 28.0M
- Free float 24.8M
HYLORIS PHARMA. S.A. company profile
- Company name
- HYLORIS PHARMA. S.A.
- Ticker
- 52U.F
- ISIN
- BE0974363955
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 54
- Fiscal year end
- December
- Address
- Boulevard Patience et Beaujonc 3/1, Liège, Belgium, 4000
- Phone
- 32 4 346 02 07
- Website
- hyloris.com
About HYLORIS PHARMA. S.A.
Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain; Podofilox gel, a topical antimycotic drug for external genital and perianal warts; Sotalol IV, an intravenous formulation of sotalol for the treatment of atrial fibrillation, and life-threatening ventricular arrhythmias; and Valacyclovir oral suspension for the treatment of herpes virus infections. It also provides Atomoxetine oral liquid for the treatment of attention deficit hyperactivity disorder; XTRAZA and Tranexamic Acid IV RTU for the prevention and treatment of excessive bleeding; HY-094 Iron IV to treat iron deficiency; and Pantoprazole IV for short-term treatment of adult patients with gastroesophageal reflux disease and a history of erosive esophagitis. In addition, the company is involved in the development of Alenura for painful bladder syndrome; Phosphate oral liquid for phosphate supplementation; and HY-095 PPI for the treatment of gastric ulcers in horses. Further, it develops Aspirin IV for acute coronary syndrome indication; Milrinone for late-stage HF with LVAD; Dofetilide IV for atrial fibrillation indication; HY-074 for acute coronary syndrome indication; Metolazone IV for congestive heart failure indication; and HY-75 for coronary heart disease indication. The company has collaboration agreements with FHP BV, Pleco Therapeutics, Vaneltix Pharma, Inc., and AFT Pharmaceuticals. Hyloris Pharmaceuticals SA was incorporated in 2012 and is headquartered in Liège, Belgium.
HYLORIS PHARMA. S.A. management
5- Mr. Stijn Van RompayCo-Founder, CEO & Director · born 1976
- Mr. Thomas JacobsenCo-Founder, Chief Business Development Officer & Executive Director · born 1975
- Mr. Christophe MarechalChief Financial Officer
- Dr. Dietmar Aichhorn Ph.D.Chief Operating Officer
- Ms. Ann De JaegerChief Legal Officer & General Secretary · born 1967